KPV + GHK-Cu Blend protocol

Standard

Weeks 1–2

5u

1 mg (blend) · Daily

SubQ. Delivers ~167 mcg KPV + ~833 mcg GHK-Cu. Assess tolerance.

Weeks 3–6

10u

2 mg (blend) · Daily

Working dose (~333 mcg KPV + ~1.7 mg GHK-Cu).

Off

2–4 weeks

Standard washout; re-cycle if needed.

Phase	How often	Dose	Units	Notes
Weeks 1–2	Daily	1 mg (blend)	5u	SubQ. Delivers ~167 mcg KPV + ~833 mcg GHK-Cu. Assess tolerance.
Weeks 3–6	Daily	2 mg (blend)	10u	Working dose (~333 mcg KPV + ~1.7 mg GHK-Cu).
Off	2–4 weeks	–	–	Standard washout; re-cycle if needed.

Units at 20 mg/mL.

Cycle & timing

Cycle: 4–6 weeks on / 2–4 weeks off.

Timing: Daily, anytime; SubQ near the area of need for local effect, or abdomen for systemic.

Where: SubQ; near the target area or abdomen. Rotate.

What to expect

Reduced inflammation (gut/skin) plus tissue-repair support over 4–6 weeks. Good for inflamed, healing tissue where both actions help.

How much to buy

For 6-wk @ 2 mg blend × 7/wk:

5

× 60mg vials

Men & women

Unisex (anti-inflammatory + copper repair), same protocol for men and women, no cycle effect. Avoid in pregnancy.

Dilution calculator

Set to the guide's typical mix for KPV + GHK-Cu Blend. Change anything to see where to draw.

Vial size

BAC water added

Dose you want

Draw to

10u

Volume

0.10 mL

Strength

20 mg/mL

Doses per vial

30

Assumes a U-100 insulin syringe (100 units = 1 mL). Double-check against the compound's page before you draw.

Recommended mixes

Vial	Water	Strength
60 mg (KPV 10 + GHK-Cu 50)	3 mL	20 mg/mL blend

60 mg (KPV 10 + GHK-Cu 50): 1 unit = 0.2 mg blend (~0.033 mg KPV + 0.167 mg GHK-Cu)

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, up to 6 weeks.

Don't use if: Active malignancy (GHK-Cu angiogenic / growth-promoting, theoretical) · Wilson’s disease / copper overload (GHK-Cu component) · Pregnancy and lactation · Hypersensitivity to either component

Stop if you notice

New mass or unexpected tissue growth
Persistent injection-site reaction
Signs of copper excess (nausea, fatigue, neurological symptoms)

Side effects

Usually minimal, injection-site reaction; possible faint blue tint from the copper. KPV is generally very well tolerated.

Drug interactions

High-dose vitamin C / ascorbic acid / strong reducers: disrupt the copper complex; Copper-chelating agents: reduce GHK-Cu activity; No major systemic drug interactions otherwise

Labs

hsCRP (inflammation) baseline + end if treating inflammation; Serum copper/ceruloplasmin if used long-term or high-dose; Out of range? Rising serum copper / ceruloplasmin = copper is accumulating → pause and re-dose lower.

What these labs mean →

Warnings

Two-peptide blend, both components’ cautions apply; Copper component: avoid copper excess; separate from high-dose vitamin C / direct acids; Tissue-repair pathways overlap with tumor growth, any new mass needs evaluation; Quality varies, request a COA

Patient education

Combines anti-inflammatory (KPV) with repair (GHK-Cu), good for inflamed, healing tissue; Both are injectable here; KPV is dosed SubQ; Keep away from high-dose vitamin C in the same session; Avoid with active cancer or copper-overload conditions; report new lumps

These apply on top of the universal safety rules.

Pairs well with

BPC-157 / TB-500 / Wolverine Blend

repair

BPC-157 TB-500 (Thymosin Beta-4) Wolverine Blend

LL-37

antimicrobial, gut

LL-37

Glutathione

anti-inflammatory

Glutathione

Avoid with

Active malignancy

GHK-Cu growth/angiogenesis, theoretical

High-dose vitamin C same session

disrupts copper complex

Pregnancy

Can KPV + GHK-Cu Blend + BPC-157 share a syringe?

Can share a syringe. Both are water-based. Combine them if you dose on the same schedule and site.

What it does

KPV (the C-terminal tripeptide of α-MSH) is a potent anti-inflammatory that calms NF-κB signaling, notable for gut (IBD-type) and skin inflammation. GHK-Cu drives copper-dependent tissue repair, collagen synthesis, and angiogenesis. The blend combines “calm the inflammation” with “rebuild the tissue.” This vial is KPV 10 mg + GHK-Cu 50 mg (60 mg total).

Note

Both components are injectable here (KPV is given SubQ, not oral); the blend targets gut/skin inflammation plus repair.

References

researchdosing peptidedosages PubMed thepeptidereport

From the guide, page 52.